Key facts
- This page summarizes Ali Behbahani's Form 4 filing for Adaptimmune Therapeutics PLC (ADAP).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 19 Aug 2025, 19:07.
Ali Behbahani - 15 Aug 2025 Form 4 Insider Report for Adaptimmune Therapeutics PLC (ADAP)
- Reporting relationship
- Director
- Issuer ticker
- ADAP
- Reported as of
- 15 Aug 2025
- Net transaction value
- -$229,172
- SEC form
- 4
- Accepted by SEC
- 19 Aug 2025, 19:07:09 UTC
- Prior SEC filing
- 14 Aug 2025
- Next SEC filing
- 22 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Zachary Bambach, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ali Behbahani filed Form 4 for Adaptimmune Therapeutics PLC (ADAP) on 19 Aug 2025.
Change
- Previous filing in this sequence was filed on 14 Aug 2025.
- Current net transaction value: -$229,172.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001613867
Primary reporting owner
Behbahani Ali
- Relationship
- Director
- Address
- 2855 SAND HILL ROAD, MENLO PARK
- Signature
- /s/ Zachary Bambach, attorney-in-fact
- Signature date
- 19 Aug 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADAP
transaction
Ordinary Shares with a nominal value of 0.001 GBP per share
Sale
- Transaction value
- $53,110
- Shares
- -4,828,206
- Change %
- -25%
- Price
- $0.0110*
- Shares after
- 14,671,794
- Date
- 15 Aug 2025
- Ownership
- See Note 3
- Footnotes
- F1, F2, F3
ADAP
transaction
Ordinary Shares with a nominal value of 0.001 GBP per share
Sale
- Transaction value
- $176,062
- Shares
- -14,671,794
- Change %
- -100%
- Price
- $0.0120*
- Shares after
- 0
- Date
- 18 Aug 2025
- Ownership
- See Note 3
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The Ordinary Shares whose sale is reported in this row are represented by American Depositary Shares ("ADSs") and are held of record by New Enterprise Associates 16, L.P. ("NEA 16"). NEA 16 holds these Ordinary Shares in the form of ADSs. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc (the "Issuer").
Footnote F2
The prices reported in Column 4 are per Ordinary Share and were derived from the price per ADS divided by six. The reported price of $0.011 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.0099 to $0.0118 per Ordinary Share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of ADSs sold at each separate price within the range set forth in this footnote.
Footnote F3
The Reporting Person is a manager of NEA 16 GP, LLC ("NEA 16 GP"), which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of NEA 16, which is the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.
Footnote F4
The prices reported in Column 4 are per Ordinary Share and were derived from the price per ADS divided by six. The reported price of $0.012 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $0.0114 to $0.0130 per Ordinary Share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of ADSs sold at each separate price within the range set forth in this footnote.